ProfileGDS5678 / 1446290_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 37% 35% 35% 32% 35% 34% 34% 34% 34% 35% 39% 35% 35% 35% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8858937
GSM967853U87-EV human glioblastoma xenograft - Control 22.7969735
GSM967854U87-EV human glioblastoma xenograft - Control 32.798835
GSM967855U87-EV human glioblastoma xenograft - Control 42.6658232
GSM967856U87-EV human glioblastoma xenograft - Control 52.7413235
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8563834
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8366134
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7720334
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7601334
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7844735
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.890339
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7692435
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7891235
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7892235